U094 Supportive Oncodermatology: A Practical Guide for the General Dermatologist
DESCRIPTION
Cutaneous reactions to chemotherapy and targeted therapies are common and often distressing, yet many general dermatologists feel underprepared to manage them. This fast-paced, practical session will review frequently encountered reactions, including toxic erythema of chemotherapy, hand-foot skin reaction, nail changes, chemotherapy-associated alopecia, and cutaneous reactions to epidermal growth factor receptor inhibitors. Attendees will learn to recognize, grade, and manage these conditions using evidence-based strategies aimed at improving patient comfort and minimizing treatment disruptions. Designed for the general dermatologist, this session will provide tools to confidently care for patients undergoing cancer treatment and collaborate effectively with oncology teams.
LEARNING OBJECTIVES
Identify common cutaneous adverse events related to chemotherapy and targeted therapies, including toxic erythema, chemotherapy-associated alopecia, nail changes, and epidermal growth factor receptor inhibitors
Distinguish between hand-foot syndrome (HFS) and hand-foot skin reaction (HFSR)
Apply evidence-based grading and management strategies to improve patient quality of life and reduce interruptions in cancer treatment
SCHEDULE
7:30 AM
Toxic erythema of chemotherapy: Recognizing clinical variants and avoiding diagnostic pitfalls
Christopher Iriarte, MD, FAAD
7:45 AM
Hair and Nail Toxicities of Chemotherapy: Clinical Patterns and Practical Management
Cuong Nguyen, MD, FAAD
8:00 AM
Cutaneous Toxicities of EGFR Inhibitors: Clinical Patterns and Practical Management
Lauren Marie Guggina, MD, FAAD
8:15 AM
Question and Answer
DIRECTOR
Cuong Nguyen, MD, FAAD
SPEAKERS
Lauren Marie Guggina, MD, FAAD
Christopher Iriarte, MD, FAAD
DISCLOSURES
Lauren Marie Guggina, MD, FAAD
No financial relationships exist with ineligible companies.
Christopher Iriarte, MD, FAAD
No financial relationships exist with ineligible companies.
Cuong Nguyen, MD, FAAD
No financial relationships exist with ineligible companies.